The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a press release.With this approval, Zevaskyn (prademagene zamikeracel ...

The FDA approved the first treatment for dystrophic epidermolysis bullosa, a devastating condition that causes the skin to be extraordinarily fragile.

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa Provided by GlobeNewswire Feb 28, 2025 4:40am ...

Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin.

Recessive dystrophic epidermolysis bullosa (RDEB) is characterized by extensive blistering and severe skin wounds caused by a mutation in the COL7A1 gene.

The FDA did not approve Abeona Therapeutics’ biologics license application for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa, the company announced in a press release ...

VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa.

“With this positive CHMP opinion we are now one step closer to offering NaMuscla™ to patients with non-dystrophic myotonia, for whom there are currently no licensed treatment options available ...

The global dystrophic epidermolysis bullosa market is driven by rising awareness, advances in early diagnosis, and improved treatment options.

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa Published Nov 27, 2023 7:00am EST ...

The FDA has accepted for Priority Review the BLA for pz-cel (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa.

VYJUVEK ® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa.